Copaxone is owned by Teva....All news received directly from Teva or it's websites is in green
Friday
Copaxone lipoatrophy far more common than reported: he risk of lipoatrophy with glatiramer acetate is greater than 60%
The risk is "substantially higher than previously reported and [is] often the sole factor prompting patients to switch to another MS [disease-modifying therapy]. Click here to read more